Universal Ibogaine Inc.
IBOGF · OTC
7/31/2022 | 7/31/2021 | 3/31/2020 | 3/31/2019 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.01 | -0.01 | 0.00 | 0.13 |
| FCF Yield | -60.44% | -27.50% | -9.81% | -7.26% |
| EV / EBITDA | -1.81 | -3.21 | 1,859.83 | -23.22 |
| Quality | ||||
| ROIC | 8.70% | -114.29% | 0.40% | -17.18% |
| Gross Margin | 100.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.41 | 0.84 | 1.03 | 0.73 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | -100.00% |
| Free Cash Flow Growth | -36.28% | -2,531.06% | -71.56% | 77.53% |
| Safety | ||||
| Net Debt / EBITDA | -0.22 | -0.07 | -113.64 | 6.05 |
| Interest Coverage | 7.34 | -255.45 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 78.74 | 0.00 | 0.00 | 0.00 |